34. Гладкова К.А., Менжинская И.В., Сухих Г.Т., Сидельникова В.М. Роль сенсибилизации к прогестерону в клинике привычного невынашивания беременности // Проблемы репродукции. 2007. С. 95-98.
35. Nagornaya V., Marichereda V. Early prophylaxis of preeclampsia in women at rick for сhanges in spiral arteries // Cnina journal of Modern Medicine. 2011. Vol.
1005-8982. P. 23-33; 35-06.
36. Schindler A.E. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium // Maturitas. 2009. Vol. 65. S3-S11. doi:10.1016/j.maturi-tas.2009.
37. L'Hermite M.L. at al. // Maturitas. 2008. Vol. 60. P. 185-201.
38. Carmichael S. at al. // Arch Pediatr Adolesc Med. 2005. Vol. 159. P. 957-962.
39. Chen J.-T., Kotani K. Different Effects of Oral Contraceptive and Dydrogesterone Treatment on Oxidative Stress Levels in Premenopausal Women // J Clin Med
Res. 2018. Vol. 10, № 2. P. 146-153.
40. Magdik I.V. Duphaston in obstetrics and gynecology practice. Medical liability //
Health of Ukraine. 2012. Vol. 2, № 6. P. 5.
41. Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage // Gyn. Endocr. 2012, Early Online: 1-8.
42. Gracia C.R., Sammel M.D., Chittams J., Hummel A.C., Shaunik A., Barn-hart K.T. Risk factor for spontaneous abortion in early symptomatic first trimester pregnancies // Obstet Gynecol. 2005. Vol. 106. P. 993-999.
43. Arck P.C., Rucke M., Rose M., Szekeres-Bartho J., Douglas A.J., Blois S.M. et al. Early risk factors for miscarriage: a prospective cohort study in pregnant women // Reprod Biomed Online. 2008. Vol. 17. P. 101-113.
44. Maconochie N., Doyle P., Prior S., Simmons R. Risk factors for first trimester misscarriage - results from a UK-population-based casecontrol study // BJOG.